228 related articles for article (PubMed ID: 31831718)
1. Bone morphogenetic protein 4 (BMP4) alleviates hepatic steatosis by increasing hepatic lipid turnover and inhibiting the mTORC1 signaling axis in hepatocytes.
Peng Q; Chen B; Wang H; Zhu Y; Wu J; Luo Y; Zuo G; Luo J; Zhou L; Shi Q; Weng Y; Huang A; He TC; Fan J
Aging (Albany NY); 2019 Dec; 11(23):11520-11540. PubMed ID: 31831718
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNA (lncRNA) H19 induces hepatic steatosis through activating MLXIPL and mTORC1 networks in hepatocytes.
Wang H; Cao Y; Shu L; Zhu Y; Peng Q; Ran L; Wu J; Luo Y; Zuo G; Luo J; Zhou L; Shi Q; Weng Y; Huang A; He TC; Fan J
J Cell Mol Med; 2020 Jan; 24(2):1399-1412. PubMed ID: 31809000
[TBL] [Abstract][Full Text] [Related]
3. Bone morphogenetic protein 4 (BMP4) promotes hepatic glycogen accumulation and reduces glucose level in hepatocytes through mTORC2 signaling pathway.
An L; Shi Q; Zhu Y; Wang H; Peng Q; Wu J; Cheng Y; Zhang W; Yi Y; Bao Z; Zhang H; Luo Y; Fan J
Genes Dis; 2021 Jul; 8(4):531-544. PubMed ID: 34179315
[TBL] [Abstract][Full Text] [Related]
4. CD38 Deficiency Protects Mice from High Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Activating NAD
Xie L; Wen K; Li Q; Huang CC; Zhao JL; Zhao QH; Xiao YF; Guan XH; Qian YS; Gan L; Wang LF; Deng KY; Xin HB
Int J Biol Sci; 2021; 17(15):4305-4315. PubMed ID: 34803499
[TBL] [Abstract][Full Text] [Related]
5. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
6. Hepatic autophagy fluctuates during the development of non-alcoholic fatty liver disease.
Ding H; Ge G; Tseng Y; Ma Y; Zhang J; Liu J
Ann Hepatol; 2020; 19(5):516-522. PubMed ID: 32553647
[TBL] [Abstract][Full Text] [Related]
7. The DEAD-box helicase DDX3x ameliorates non-alcoholic fatty liver disease via mTORC1 signalling pathway.
Liu P; Zhang Y; Tang C; Cen L; Chen Y; Li S; Chen X; Yu M; Zhang J; Zhang X; Zeng H; Xu C; Yu C
Liver Int; 2022 Aug; 42(8):1793-1802. PubMed ID: 35460172
[TBL] [Abstract][Full Text] [Related]
8. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
9. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
[TBL] [Abstract][Full Text] [Related]
10. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
11. Oxygen therapy alleviates hepatic steatosis by inhibiting hypoxia-inducible factor-2α.
Yu L; Wang H; Han X; Liu H; Zhu D; Feng W; Wu J; Bi Y
J Endocrinol; 2020 Jul; 246(1):57-67. PubMed ID: 32369776
[TBL] [Abstract][Full Text] [Related]
12. Lipotoxicity-induced STING1 activation stimulates MTORC1 and restricts hepatic lipophagy.
Liu K; Qiu D; Liang X; Huang Y; Wang Y; Jia X; Li K; Zhao J; Du C; Qiu X; Cui J; Xiao Z; Qin Y; Zhang Q
Autophagy; 2022 Apr; 18(4):860-876. PubMed ID: 34382907
[TBL] [Abstract][Full Text] [Related]
13. Tuberous sclerosis complex-1 deficiency attenuates diet-induced hepatic lipid accumulation.
Kenerson HL; Yeh MM; Yeung RS
PLoS One; 2011 Mar; 6(3):e18075. PubMed ID: 21479224
[TBL] [Abstract][Full Text] [Related]
14. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
[TBL] [Abstract][Full Text] [Related]
15. Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance.
Kim HY; Park SY; Lee MH; Rho JH; Oh YJ; Jung HU; Yoo SH; Jeong NY; Lee HJ; Suh S; Seo SY; Cheong J; Jeong JS; Yoo YH
J Hepatol; 2015 Aug; 63(2):477-85. PubMed ID: 25646886
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of long non-coding RNA Gm10804 suppresses disorders of hepatic glucose and lipid metabolism in diabetes with non-alcoholic fatty liver disease.
Li T; Huang X; Yue Z; Meng L; Hu Y
Cell Biochem Funct; 2020 Oct; 38(7):839-846. PubMed ID: 32212193
[TBL] [Abstract][Full Text] [Related]
17. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.
Liu J; Tang T; Wang GD; Liu B
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
[No Abstract] [Full Text] [Related]
18. Zinc alpha2 glycoprotein protects against obesity-induced hepatic steatosis.
Xiao XH; Wang YD; Qi XY; Wang YY; Li JY; Li H; Zhang PY; Liao HL; Li MH; Liao ZZ; Yang J; Xu CX; Wen GB; Liu JH
Int J Obes (Lond); 2018 Aug; 42(8):1418-1430. PubMed ID: 30006580
[TBL] [Abstract][Full Text] [Related]
19. FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.
Liu C; Zhou B; Meng M; Zhao W; Wang D; Yuan Y; Zheng Y; Qiu J; Li Y; Li G; Xiong X; Bian H; Zhang H; Wang H; Ma X; Hu C; Xu L; Lu Y
J Hepatol; 2021 Jul; 75(1):150-162. PubMed ID: 33548387
[TBL] [Abstract][Full Text] [Related]
20. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
